Pemphigus vulgaris News and Research

RSS

Pemphigus vulgaris is a rare autoimmune disease that causes blistering of the skin and mucous membranes of the mouth, throat and genital area.

Drug regimen for lymphoma and RA more likely to put patients with pemphigus into remission

Pemphigus, an autoimmune disease mediated by B cells and which causes painful blisters and sores on the skin and mucous membranes, is a rare chronic autoimmune condition that can be fatal if not treated.

11 Nov 2019

CAR-T cell therapy could be on the horizon for patients with lupus

Researchers have developed a novel CAR-T cell therapy that can reduce B cell numbers known to cause the inflammatory responses in lupus.

7 Mar 2019

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.

22 Oct 2018

Two new studies find potential genetic cause and new treatment method for autoimmune diseases

The American Autoimmune Related Diseases Association, Inc. is spotlighting two new research studies originally reported in ScienceDaily.

13 Jul 2016

New strategy treats fatal autoimmune disease without outward off-target effects

In a study with potentially major implications for the future treatment of autoimmunity and related conditions, scientists from the Perelman School of Medicine at the University of Pennsylvania have found a way to remove the subset of antibody-making cells that cause an autoimmune disease, without harming the rest of the immune system.

4 Jul 2016

Researchers discover new details of how autoantibodies destroy healthy cells in skin

University at Buffalo researchers and colleagues studying a rare, blistering disease have discovered new details of how autoantibodies destroy healthy cells in skin.

11 Sep 2014

Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Lyfebulb, the International Pemphigus Pemphigoid Foundation (IPPF) and Immune Pharmaceuticals Inc., announced a collaboration to increase awareness of unmet needs in treating bullous pemphigoid last night at an event attended by more than sixty patients, physicians, scientists and other interested parties.

24 Jul 2014

Researchers find shared genetic link in autoimmune response among PV patients

Autoimmune disease occurs when the body's own natural defense system rebels against itself. One example is pemphigus vulgaris (PV), a blistering skin disease in which autoantibodies attack desmoglein 3 (Dsg3), the protein that binds together skin cells.

19 Jun 2014